About InCode BioPharmaceutics
Incode BioPharmaceutics, Inc., has developed a product candidate, HC3-1496, that specifically targets the complement pathway. The mechanism-of-action of HC3-1496 results in enzymatic depletion of the complement protein C3, the key component for all three pathways of complement activation (alternative, classical, and mannose-lectin). The company's preclinical results show rapid depletion of C3 without any observed adverse events, including in primates. Importantly, HC3-1496 depletes C3 without the downstream activation of C5, thus preventing the formation of the C5a anaphylatoxin. A recent exciting result is the demonstration that HC3-1496 enhances the efficacy of an anti-CD20 mAb in a murine cancer model. These data will be presented at the upcoming American Society of Hematology (ASH) meeting in December. This clinical avenue is a high priority for InCode, and also underscores the increased appreciation for the role of complement in certain oncologic settings. The company have also demonstrated efficacy in several other animal models of human disease, including collagen-induced arthritis (RA), myocardial ischemia/reperfusion, and age related macular degeneration (AMD). The company have also demonstrated that HC3-1496 prevents the lysis of erythrocytes in patients with paroxysmal nocturnal hemoglobinuria (PNH). Given the emerging role of complement activation in the pathogenesis of grievous human disease, Incode intends to exploit the potent activity of HC3-1496. The company intend to initiate human clinical trials in selected indications within 18 months.
InCode BioPharmaceutics Frequently Asked Questions (FAQ)
When was InCode BioPharmaceutics founded?
InCode BioPharmaceutics was founded in 2006.
Where is InCode BioPharmaceutics's headquarters?
InCode BioPharmaceutics's headquarters is located at 50 Puu Anoano Road, Lahaina.
What is InCode BioPharmaceutics's latest funding round?
InCode BioPharmaceutics's latest funding round is Series B.
How much did InCode BioPharmaceutics raise?
InCode BioPharmaceutics raised a total of $3M.
Who are the investors of InCode BioPharmaceutics?
Investors of InCode BioPharmaceutics include Avalon Ventures.
Who are InCode BioPharmaceutics's competitors?
Competitors of InCode BioPharmaceutics include Philogen, Keryx Biopharmaceuticals, BioMarck Pharmaceuticals, Raptor Pharmaceutical Corp., Jennerex Biotherapeutics and 14 more.
Compare InCode BioPharmaceutics to Competitors
BioVascular Inc. is a privately held biotechnology company that develops drugs and devices for the control of intimal hyperplasia associated with vascular procedures and control of risk factors associated with cardiovascular morbidity and mortality. BioVascular's lead product, saratin, is a polypeptide produced by recombinant means in yeast. This product was licensed from Merck, KGaA in 2005. BioVascular began human clinical trials of saratin for hemodialysis graft access in late 2006 and will begin human trials in the treatment of peripheral artery grafts in early 2007. BioVascular's second product utilizes a mechanism for reduction of a recently defined cardiovascular risk factor. This product will enter human studies in mid 2007.
Longevica is a biotechnology that is researching mechanisms of healthy aging and life extension. The company is also developing an open research tool for scientists and research institutions to access a data set that tracks the effects of pharmacological compounds for testing drugs.
REPLICor is a biopharmaceutical company developing first-in-class entry inhibitors for the treatment of hepatitis C (HCV) and prevention of HCV re-infection following liver transplantation. The company also targets the hepatitis B and influenza markets. The lead compound REP 9AC is a broad-spectrum antiviral having potent activity against HCV, HBV, influenza and other enveloped viruses. The compound is active by multiple routes of administration and is well tolerated. The company business strategy is to enter into alliances with major biopharmaceutical companies in order to further develop and market its product.
Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.
Bolder BioTechnology, Inc. uses advanced protein engineering technologies to create human protein pharmaceuticals with enhanced therapeutic properties. Most protein pharmaceuticals are rapidly eliminated by the body, which limits their effectiveness and requires that they be administered by frequent, often daily, injection. The company's products are designed to last longer in the body, which aims to allow them to be administered less frequently, e.g., once per week to once per month, and maximizes their therapeutic benefits to patients. Company scientists combine protein structure/function information with targeted protein modification technologies to rationally design long-acting protein pharmaceuticals that, in many cases, are 10-100-fold more potent than competing products prepared using non-targeted protein modification technologies. Bolder BioTechnology has a robust pipeline of products in preclinical development, including products for the treatment of hematological and endocrine disorders, cancer and infectious disease. The company intend to commercialize these products independently and through strategic alliances with corporate partners.
Sunzen Biotech Berhad ("Sunzen Biotech"‚) is an animal health specialist, focused on developing, manufacturing and marketing animal health care products. The company market a range of animal health products which includes feed additives, nutritional feed supplements, veterinary pharmaceuticals, animal vaccines and other animal health care products for livestock such as poultry, swine, goats and cattle, as well as companion animals. The company develop and manufacture non-antibiotic animal health products that comply with international safety standards to ensure public safety. And in recognition of the company's focused Research and Development in non-antibiotic animal biotechnology, Sunzen Biotech has been accorded BioNexus Status, which entitles Sunzen to tax incentives and other privileges specified under the Bionexus bill of guarantees, from the Malaysian Biotechnology Corporation. Sunzen is also the sole distributor for Pfizer Animal Health products in Malaysia, Singapore, andnBrunei. The company are proud to say that today "Sunzen"‚ products are supplied to feed millers and livestock producers in Malaysia and across the region.